StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for NXL yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $0.34 | $0.32 | -3.85% | 0.2M |
| 05-19 | $0.31 | $0.32 | +2.92% | 0.7M |
| 05-20 | $0.32 | $0.34 | +5.74% | 0.2M |
| 05-21 | $0.35 | $0.40 | +14.00% | 1.9M |
| 05-22 | $0.43 | $0.38 | -11.88% | 17.4M |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $14.95K | $301.65K | $129.75K | $111.60K |
Operating Income | $-2.12M | $-8.39M | $-5.98M | $-3.63M |
Net Income | $-2.10M | $-8.22M | $-5.85M | $-3.57M |
EPS (Diluted) | $-0.11 | $-0.50 | $-0.37 | $-0.25 |
Total Assets | $3.69M | $4.64M | $5.13M | $6.56M |
Total Liabilities | $808.36K | $887.33K | $357.52K | $600.58K |
Cash & Equivalents | $1.21M | $654.78K | $590.08K | $431.32K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 20.58M | 19.19M | 18.19M | 17.42M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.